Join us virtually on February 17th at 3pm PST | 6 PM EST as Dr. Hande Ozdinler describes the groundbreaking work underway that looks at the brain motor neurons as a target for developing ALS therapies.

Join us virtually on November 10th at 1pm PST for an update on the HEALEY ALS Platform Trial with Dr. Sabrina Paganoni.

We'll cover:

• The status of current trial drug regimens.

• What treatment regimens are currently enrolling.

• Who qualifies for the drug treatments currently enrolling.

• The outlook for additional treatments to be added in the future.

• + an open Q&A session

Speaker & Moderator:

Dr. Sabrina Paganoni is the Co-Principal Investigator of the HEALEY ALS Platform Trial, Co-Director of the Neurological Clinical Research Institue, Mass General Hospital, and an Assistant Professor at Harvard Medical School/Spaulding Rehabilitation Hospital

Taner Dagdelen is the CEO & Co-Founder of Unite Genomics.

Learn how the Harms Lab is working to better understand the genetics behind ALS and how different genes contribute to different forms of ALS. This information could help researchers and clinicians better tailor therapeutic interventions to an individual’s genetic profile.

Tune into this upcoming webinar to see how the Unite Portal works and get your questions answered!